Gwen Knight
Title
Cited by
Cited by
Year
The transmission of Mycobacterium tuberculosis in high burden settings
TA Yates, PY Khan, GM Knight, JG Taylor, TD McHugh, M Lipman, ...
The Lancet infectious diseases 16 (2), 227-238, 2016
1112016
Shift in dominant hospital-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) clones over time
GM Knight, EL Budd, L Whitney, A Thornley, H Al-Ghusein, T Planche, ...
Journal of Antimicrobial Chemotherapy 67 (10), 2514-2522, 2012
1092012
Impact and cost-effectiveness of new tuberculosis vaccines in low-and middle-income countries
GM Knight, UK Griffiths, T Sumner, YV Laurence, A Gheorghe, A Vassall, ...
Proceedings of the National Academy of Sciences 111 (43), 15520-15525, 2014
1042014
Estimating the burden of antimicrobial resistance: a systematic literature review
NR Naylor, R Atun, N Zhu, K Kulasabanathan, S Silva, A Chatterjee, ...
Antimicrobial Resistance & Infection Control 7 (1), 58, 2018
792018
The complex evolution of antibiotic resistance in Mycobacterium tuberculosis
JD Fonseca, GM Knight, TD McHugh
International journal of infectious diseases 32, 94-100, 2015
692015
Metformin reduces airway glucose permeability and hyperglycaemia-induced Staphylococcus aureus load independently of effects on blood glucose
JP Garnett, EH Baker, S Naik, JA Lindsay, GM Knight, S Gill, JS Tregoning, ...
Thorax 68 (9), 835-845, 2013
642013
The distribution of fitness costs of resistance-conferring mutations is a key determinant for the future burden of drug-resistant tuberculosis: a model-based analysis
GM Knight, C Colijn, S Shrestha, M Fofana, F Cobelens, RG White, ...
Clinical Infectious Diseases 61 (suppl_3), S147-S154, 2015
372015
Systematic review of mathematical models exploring the epidemiological impact of future TB vaccines
RC Harris, T Sumner, GM Knight, RG White
Human vaccines & immunotherapeutics 12 (11), 2813-2832, 2016
352016
Within-host diversity of MRSA antimicrobial resistances
KI Stanczak-Mrozek, A Manne, GM Knight, K Gould, AA Witney, ...
Journal of Antimicrobial Chemotherapy 70 (8), 2191-2198, 2015
352015
Bridging the gap between evidence and policy for infectious diseases: How models can aid public health decision-making
GM Knight, NJ Dharan, GJ Fox, N Stennis, A Zwerling, R Khurana, ...
International journal of infectious diseases 42, 17-23, 2016
302016
Predicting the long-term impact of antiretroviral therapy scale-up on population incidence of tuberculosis
PJ Dodd, GM Knight, SD Lawn, EL Corbett, RG White
PloS one 8 (9), 2013
302013
Ebola: the power of behaviour change
S Funk, GM Knight, VAA Jansen
Nature 515 (7528), 492-492, 2014
232014
Large mobile genetic elements carrying resistance genes that do not confer a fitness burden in healthcare-associated meticillin-resistant Staphylococcus aureus
GM Knight, EL Budd, JA Lindsay
Microbiology 159 (8), 1661-1672, 2013
212013
Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling
GM Knight, CF McQuaid, PJ Dodd, RMGJ Houben
The Lancet Infectious Diseases 19 (8), 903-912, 2019
202019
Shuffling of mobile genetic elements (MGEs) in successful healthcare-associated MRSA (HA-MRSA)
JA Lindsay, GM Knight, EL Budd, AJ McCarthy
Mobile genetic elements 2 (5), 239-243, 2012
192012
Drivers and trajectories of resistance to new first-line drug regimens for tuberculosis
S Shrestha, GM Knight, M Fofana, T Cohen, RG White, F Cobelens, ...
Open forum infectious diseases 1 (2), 2014
182014
A multistrain mathematical model to investigate the role of pyrazinamide in the emergence of extensively drug-resistant tuberculosis
MO Fofana, S Shrestha, GM Knight, T Cohen, RG White, F Cobelens, ...
Antimicrobial agents and chemotherapy 61 (3), e00498-16, 2017
172017
Population-level impact of shorter-course regimens for tuberculosis: a model-based analysis
MO Fofana, GM Knight, GB Gomez, RG White, DW Dowdy
PloS one 9 (5), 2014
162014
Tuberculosis prevention in South Africa
GM Knight, PJ Dodd, AD Grant, KL Fielding, GJ Churchyard, RG White
PloS one 10 (4), 2015
152015
The TB vaccine H56+ IC31 dose-response curve is peaked not saturating: data generation for new mathematical modelling methods to inform vaccine dose decisions
SJ Rhodes, A Zelmer, GM Knight, SA Prabowo, L Stockdale, TG Evans, ...
Vaccine 34 (50), 6285-6291, 2016
102016
The system can't perform the operation now. Try again later.
Articles 1–20